Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cytokine-induced Killer(CIK) Cell Therapy and Its Impact on Early Functional Exhaustion of Chimeric Antigen Receptor-T(CAR-T) Cells in Relapsed or Refractory Acute B-Lymphoblastic Leukemia: A Prospective Study

NCT06389305 is registered in ClinicalTrials.gov with Beijing GoBroad Hospital as lead sponsor.

NCT NCT06389305
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06389305 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cytokine-induced Killer(CIK) Cell Therapy and Its Impact on Early Functional Exhaustion of Chimeric Antigen Receptor-T(CAR-T) Cells in Relapsed or Refractory Acute B-Lymphoblastic Leukemia: A Prospective Study
Lead sponsor
Beijing GoBroad Hospital
Phase
Not applicable
Overall status
Recruiting
Start date
May 27, 2024
Completion date
May 30, 2026
Enrollment
213 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, in relapse, b-cell acute lymphoblastic leukemia, refractory acute lymphoid leukemia